Bupropion effects in attention deficit and conduct disorders

Area of Science:

• Child and Adolescent Psychiatry
• Neuroscience
• Pharmacology

Background:

• Attention Deficit Disorder (ADHD) and Conduct Disorders (CD) are prevalent in children.
• Limited effective pharmacological options exist for these pediatric psychiatric conditions.
• Bupropion, an antidepressant, has not been extensively studied in pediatric populations with ADHD/CD.

Purpose of the Study:

• To evaluate the clinical, cognitive, and electroencephalogram (EEG) effects of bupropion in children with ADHD and/or CD.
• To assess the safety and tolerability of bupropion in this pediatric cohort.

Main Methods:

• An open-label clinical trial involving 17 male patients (ages 7-13.4 years) with ADHD/CD.
• A 4-week placebo baseline, followed by 8 weeks of bupropion treatment (max 150 mg/day), and a 2-week post-drug placebo period.
• Evaluations included clinical assessments (Children's Psychiatric Rating Scale, Parents' Questionnaires), cognitive tests, blood levels, EEG, and vital signs.

Main Results:

• Significant clinical global improvement was observed in 12 out of 14 patients treated with bupropion.
• Improvements were noted across hyperactivity, conduct problems, anxiety, depression, and other behavioral symptoms.
• While no single cognitive test reached statistical significance, all showed positive directional changes; adverse effects were mild and transient.
• EEG analyses indicated significant bupropion effects, correlating with clinical improvement.

Conclusions:

• Bupropion demonstrated a favorable clinical and EEG profile in children with Attention Deficit and/or Conduct Disorders.
• The drug was generally well-tolerated, with infrequent and mild side effects.
• Double-blind, placebo-controlled trials are warranted to confirm these findings in pediatric psychiatric disorders.